Company news

Fate Therapeutics, Inc. news in 2025

Fate Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

December 7, 2025

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

November 24, 2025

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

November 12, 2025

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

October 25, 2025

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

October 13, 2025

Fate Therapeutics to Present at Upcoming Investor Conferences

August 24, 2025

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

August 11, 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

June 10, 2025

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 29, 2025

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 27, 2025

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 12, 2025

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

April 28, 2025

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

April 13, 2025

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 4, 2025

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

March 3, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 4, 2025

Decks in 2025